Regensburg, Germany – May 6, 2025 – Lifespin GmbH, a frontrunner in personalized medical solutions, announces securing a grant from Bavarian Ministery for Economic Affairs through the Bayerisches Technologieförderungs-Programm plus (TPP) for its innovative project, OncoSpin: A Data- and AI-Based System for Monitoring Cancer Treatment and Follow-Up Care. This crucial funding endorses the project’s capacity to transform cancer treatment and strengthens Lifespin’s standing as an innovator in AI-powered metabolomics.
The OncoSpin initiative utilizes Lifespin’s state-of-the-art nuclear magnetic resonance (NMR) technology and exclusive database containing over 250,000 metabolomic profiles to create an advanced system for continuous monitoring of cancer patients. By combining efficient metabolomic testing with advanced AI systems, OncoSpin helps doctors monitor treatment effectiveness, identify early risk indicators, and customize treatment strategies for patients with cancer, demonstrated within the project for breast, prostate, and lung cancer. This breakthrough approach aims to improve patient care, decrease medical expenses, and enhance clinical efficiency.
“This grant demonstrates the impact of Lifespin’s mission to revolutionize cancer treatment through advanced metabolomic profiling,” stated Dr. Roland Geyer, Chief Operating Officer at Lifespin GmbH. “OncoSpin will provide oncologists with vital data insights, enabling more targeted and personalized treatment while bridging key gaps in therapy monitoring and aftercare.”
Working alongside the Medical University of Graz and Biobank Graz, OncoSpin will develop and test its prototype using historical and new data, ensuring smooth clinical implementation. The three-year project will result in a Research Use Only (RUO) solution, setting the stage for regulatory certification and worldwide distribution through Lifespin’s cloud-based SaaS platform.
Backed by a €1.02 million investment, including €460,000 in funding, OncoSpin will boost economic development by generating specialized jobs in Regensburg and building connections with prominent clinical and laboratory partners. The initiative supports Bavaria’s focus on advancing digital and personalized healthcare, establishing the region as a worldwide hub for medical innovation.
Lifespin GmbH thanks the Bavarian Ministery for Economic Affairs for their backing and mutual commitment to enhancing patient care through innovative technology. As OncoSpin develops, it aims to transform cancer treatment monitoring, offering an expandable, cost-effective solution that improves clinical decisions and patient outcomes globally.
About Lifespin GmbH: Lifespin GmbH, headquartered in Regensburg, Germany, is a pioneer in NMR-based metabolomics, delivering innovative solutions for proactive health assessment. With a robust database of over 250,000 metabolic profiles and a commitment to data-driven innovation, Lifespin is shaping the future of personalized healthcare globally. For more information, visit www.lifespin.health.
Media Contact
Dr. Roland Geyer
Lifespin GmbH
Email: roland.geyer@lifespin.health
Phone: +49 941 94289815
